Skip to main content

Advertisement

Table 1 Baseline characteristics for the total number of study subjects and according to treatment group

From: The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial

  Total (n = 364) Placebo (n = 188) Galantamine (n = 176) P valuea
Age 68 (8.8) 69 (8.6) 68 (9.0) 0.13
Sex, female 49 54 43 0.04
Hypertension 44 45 43 0.62
Diabetes 7 7 7 0.98
Elevated cholesterol 34 35 32 0.59
Smoking 9 10 7 0.46
ADAS-Cog/MCI 15 (7.0) 14 (6.9) 15 (7.2) 0.56
Whole brain (ml) 1,089 (124) 1,081 (124) 1,097 (123) 0.22
Hippocampal volume (ml) 5.85 (0.9) 5.78 (0.9) 5.93 (0.9) 0.11
  1. Data presented as means (standard deviation) or percentages. ADAS-Cog, Alzheimer’s Disease Assessment Scale – cognitive subscale; MCI, mild cognitive impairment. aP values for differences in means or percentages between patients treated with placebo and those treated with galantamine.